Price (delayed)
$5.15
Market cap
$160.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.71
Enterprise value
$129.56M
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively
There are no recent dividends present for PDSB.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.